| P50 | author | Gloria Garrabou | Q41652911 |
| | Constanza Morén | Q43271791 |
| | Sergio Barroso | Q92240680 |
| P2093 | author name string | José L Blanco | |
| | Josep Mallolas | |
| | Esteban Martínez | |
| | Elisa de Lazzari | |
| | Jose M Gatell | |
| | Oscar Miró | |
| | Xavier Carné | |
| | Jaume Llopis | |
| | Neus Riba | |
| | Gemina Santana | |
| | Joan A Arnaiz | |
| | Montse Loncà | |
| | Àlex González-Segura | |
| | Marcela Manriquez | |
| | María Larousse | |
| P2860 | cites work | A historical sketch of the discovery and development of HIV-1 integrase inhibitors | Q28274166 |
| | Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy | Q33745859 |
| | Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial | Q33945171 |
| | HIV protease inhibitor-related lipodystrophy syndrome | Q33946902 |
| | Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study | Q34091370 |
| | Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets | Q34664366 |
| | Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study | Q35106654 |
| | Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study | Q35195035 |
| | Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial | Q35546757 |
| | Cardiovascular risk and body-fat abnormalities in HIV-infected adults | Q36000980 |
| | Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. | Q36009838 |
| | Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines | Q36018903 |
| | Enfuvirtide: a review of its use in the management of HIV infection | Q36133801 |
| | HIV entry inhibitors: a new generation of antiretroviral drugs. | Q36262437 |
| | Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial | Q36759898 |
| | Mitochondrial disorders among infants exposed to HIV and antiretroviral therapy | Q36941813 |
| | New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists | Q37191941 |
| | Gender differences in pharmacological response | Q37301507 |
| | A review of the toxicity of HIV medications | Q37633495 |
| | Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. | Q37787703 |
| | HIV treatment and associated mitochondrial pathology: review of 25 years of in vitro, animal, and human studies | Q38143466 |
| | Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over | Q38958267 |
| | Estrogens regulate life and death in mitochondria | Q39236899 |
| | Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor | Q39652630 |
| | Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp | Q40108634 |
| | Placental Mitochondrial Toxicity, Oxidative Stress, Apoptosis, and Adverse Perinatal Outcomes in HIV Pregnancies Under Antiretroviral Treatment Containing Zidovudine | Q40318981 |
| | Depolarization of mitochondrial membrane potential is the initial event in non-nucleoside reverse transcriptase inhibitor efavirenz induced cytotoxicity | Q40577108 |
| | Continuous intravenous infusion of enfuvirtide in a patient with a multidrug-resistant HIV strain | Q40674380 |
| | Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy | Q41257241 |
| | Differentially altered molecular signature of visceral adipose tissue in HIV-1-associated lipodystrophy | Q42261327 |
| | Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients | Q42626443 |
| | Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir | Q42823707 |
| | Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. | Q43209248 |
| | Genetic and functional mitochondrial assessment of HIV-infected patients developing HAART-related hyperlactatemia | Q43271718 |
| | Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). | Q43296433 |
| | In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. | Q43501150 |
| | Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. | Q44340780 |
| | Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia | Q44457921 |
| | Short communication: HIV infection, antiretrovirals, and apoptosis: studies on skeletal muscle | Q44823225 |
| | Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial | Q45405108 |
| | Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes. | Q46614065 |
| | A safety evaluation of raltegravir for the treatment of HIV. | Q47377203 |
| | Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance | Q47886909 |
| | Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel | Q50105738 |
| | Drug-Induced Mitochondrial Toxicity. | Q51538858 |
| | Statistics in medicine--reporting of subgroup analyses in clinical trials. | Q51899945 |
| | Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprotein(a), and apolipoproteins A-I and B. | Q52379028 |
| | Mitochondrial evolution in HIV-infected children receiving first- or second-generation nucleoside analogues. | Q54322317 |
| | Class of Antiretroviral Drugs and the Risk of Myocardial Infarction | Q57181081 |
| | Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial | Q61808524 |
| | Are new antiretroviral treatments increasing the risks of clinical obesity? | Q64231621 |
| | Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically | Q80217242 |
| | Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial | Q83370365 |
| | Clinical Pharmacology in HIV Therapy | Q88909466 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | raltegravir | Q421552 |
| P304 | page(s) | e0216712 | |
| P577 | publication date | 2019-05-23 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers | |
| P478 | volume | 14 | |